Skin Impacts and Tradeoffs of GLP-1 Therapy: Improved Patient-Reported Outcomes of Inflammatory Skin Disease in the Era of “Ozempic Face”

• by Saroja Rao, Isabella Midura, Kathyana P. Santiago Mangual, Leon I. Igel, Katherine H. Saunders, Jocelyn Carter, Jenny E. Murase, Arianne Shadi Kourosh

• August 11, 2026

Longitudinal Performance of the Psoriasis Epidemiology Screening Tool (PEST) in Canada and Latin America: Results from the Prospective, Observational, 5-Year PURE Registry

• by Jennifer Beecker, Lorne Albrecht, Ignacio Dei-Cas, Melinda Gooderham, Charles Lynde, Kim A. Papp, Paul Keown, Antonio Vieira, Mahmoud S. Farag, Marie Maguin, Tanya Zappitelli, Philip S. Helliwell

• July 21, 2026

Psoriasis–AD Switching May Mimic Treatment Failure

Recognizing sustained switches between the two diseases can prevent premature discontinuation of effective biologics and point toward Janus kinase inhibitors, a 148-patient cohort suggests.

• by Andrea Surnit

• June 15, 2026

• 4 min

The therapeutic potential of natural products for pediatric psoriasis: targeting the immune microenvironment

• by Zitong Wang, Jingyu Zhang, Suwen Liu, Hongxiang Chen

• June 24, 2026